small molecule

DAYVIGO

LEMBOREXANT

Loss of exclusivityOctober 2035latest FDA-listed patent expiry

CompanyEisai →View the full company profile on CliffBio

Drug detail

Brand name	DAYVIGO
Active ingredient	LEMBOREXANT
Strength	10MG
Dosage form	TABLET
Route	ORAL
Modality	Small molecule
FDA approval	April 2020
Marketing status	RX

Listed patents

Patent	Expires	Type
10188652	October 2035	product
10702529	October 2035	product
11026944	October 2035	product
8268848	September 2031	substance, product

Regulatory exclusivity

Code	Expires
M-293	April 2026

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

Drug detail

Listed patents

Regulatory exclusivity

More from Eisai